<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1988-348X</journal-id>
<journal-title><![CDATA[Ene]]></journal-title>
<abbrev-journal-title><![CDATA[Ene.]]></abbrev-journal-title>
<issn>1988-348X</issn>
<publisher>
<publisher-name><![CDATA[Martín Rodríguez Álvaro]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1988-348X2024000100006</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Anticuerpos monoclonales biespecíficos: cuidados de enfermería a propósito de un caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Bispecific monoclonal antibodies: nursing care for the object of a case]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Medina-Cruz]]></surname>
<given-names><![CDATA[Erik]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Duchement-Alarcón]]></surname>
<given-names><![CDATA[Amalia]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Suarez]]></surname>
<given-names><![CDATA[Miriam]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Calero-Rodríguez]]></surname>
<given-names><![CDATA[Ana Cristina]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Molina-Padilla]]></surname>
<given-names><![CDATA[Sara]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santaolalla-Mondejar]]></surname>
<given-names><![CDATA[Carolina]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Simón]]></surname>
<given-names><![CDATA[Nuria]]></given-names>
</name>
</contrib>
</contrib-group>
<aff id="A">
<institution><![CDATA[,  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>18</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1988-348X2024000100006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1988-348X2024000100006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1988-348X2024000100006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El cáncer sigue siendo una enfermedad de primera magnitud a nivel mundial y uno de los pilares para su supervivencia son los tratamientos antineoplásicos. En este contexto cabe destacar el uso de los anticuerpos monoclonales, en concreto, en los anticuerpos monoclonales biespecíficos. Dada la complejidad de estos tipos de tratamientos y sus efectos secundarios, es necesaria la formación en cuidados de enfermería específicos, con profesionales que tengan los conocimientos necesarios para garantizar una vigilancia adecuada a estos pacientes. Es por ello que el objetivo principal de este estudio es exponer la realización y ejecución del Plan de Cuidados de Enfermería a una paciente con diagnóstico de Linfoma B del alto grado, que ha recibido tratamiento con Epcoritamab en el Hospital Universitario de Canarias. Así, en este artículo se realizó una valoración de enfermería según los patrones funcionales de Marjory Gordon y se desarrolló un Plan de Cuidados Individualizado (PCI) centrado en los siguientes diagnósticos: náuseas, patrón respiratorio ineficaz, riesgo de shock y riesgo de confusión aguda. En conclusión, la aplicación del PCI permitió no solamente observar los efectos secundarios mas comunes en la administración de agentes monoclonales biespecíficos, además de garantizar una monitorización continua de los cuidados con la nomenclatura empleada y caracterizada por ser universal (NANDA- NIC. NOC).]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Cancer continues to be a disease of the first magnitude worldwide and one of the pillars for its survival are antineoplastic treatments. In this context, the use of monoclonal antibodies, specifically bispecific monoclonal antibodies, should be highlighted. Given the complexity of these types of treatments and their side effects, training in specific nursing care is necessary, with professionals who have the necessary knowledge to ensure adequate monitoring of these patients. For this reason, the main objective of this study is to present the implementation and execution of the Nursing Care Plan for a patient with a diagnosis of high grade B lymphoma, who received treatment with Epcoritamab at the University Hospital of the Canary Islands. Thus, in this article a nursing assessment was performed according to Marjory Gordon's functional patterns and an Individualized Care Plan (ICP) was developed focusing on the following diagnoses: nausea, ineffective respiratory pattern, risk of shock and risk of acute confusion. In conclusion, the application of the ICP allowed not only to observe the most common side effects in the administration of bispecific monoclonal agents, but also to guarantee continuous monitoring of care with the nomenclature used and characterized by being universal (NANDA- NIC. NOC).]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Neoplasias]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos monoclonales]]></kwd>
<kwd lng="es"><![CDATA[atención de enfermería]]></kwd>
<kwd lng="es"><![CDATA[enfermería oncológica]]></kwd>
<kwd lng="es"><![CDATA[planificación de atención al paciente]]></kwd>
<kwd lng="en"><![CDATA[Neoplasms]]></kwd>
<kwd lng="en"><![CDATA[monoclonal antibodies]]></kwd>
<kwd lng="en"><![CDATA[nursing care]]></kwd>
<kwd lng="en"><![CDATA[oncology nursing]]></kwd>
<kwd lng="en"><![CDATA[patient care planning]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina Villaverde]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El paciente oncológico del siglo XXI. Maridaje terapéutico Nutrición-Oncología]]></article-title>
<source><![CDATA[Nutr Hosp]]></source>
<year>2016</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-10</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Cardona]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Historia del cáncer y el cáncer es historia]]></article-title>
<source><![CDATA[Med]]></source>
<year>2020</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>528-62</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>GLOBOCAN 2020</collab>
<source><![CDATA[Internacional Agency for Research on Cancer]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>GLOBOCAN 2020</collab>
<source><![CDATA[Internacional Agency for Research on Cancer]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Navarro-Almenzar]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno Belmonte]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez Espuch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linfomas]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2020</year>
<volume>13</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1125-32</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Valero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Matas-Céspedes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arenas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Carreras]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Serrat]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma]]></article-title>
<source><![CDATA[Leukemia]]></source>
<year>2021</year>
<volume>35</volume>
<page-range>2635-49</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campagme]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer: comunicar el diagnóstico y el pronóstico]]></article-title>
<source><![CDATA[Semergen]]></source>
<year>2019</year>
<volume>45</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>273-83</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>Sociedad Española de Oncología Médica</collab>
<source><![CDATA[Historia de la Oncología Médica en España]]></source>
<year>2009</year>
<edition>1ª</edition>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Española de Oncología Médica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inogés]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Calvillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[López Díaz de Cerio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zabalegui]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Melero]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Ibarrola]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunoterapia activa en el tratamiento de neoplasias hematológicas]]></article-title>
<source><![CDATA[Anales Sis San Navarra]]></source>
<year>2004</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-62</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bermúdez Carvajar]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hidalgo Carrillo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mora Mara]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Mora]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Ysamel-Acle]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mora Román]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticuerpos Monoclonales biespecíficos: desarrollo, producción y uso como terapia anticancerígena]]></article-title>
<source><![CDATA[Revista Médica de la Universidad de Costa Rica]]></source>
<year>2019</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-29</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Creus]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Massó]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Codina]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ribas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticuerpos monoclonales en Oncologia]]></article-title>
<source><![CDATA[Farmacia Hospitalaria]]></source>
<year>2022</year>
<volume>2381</volume>
<page-range>40-57</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>Cancer Research Institute</collab>
<source><![CDATA[Anticuerpos monoclonales, conjugados anticuerpos-fármacos y anticuerpos biespecíficos]]></source>
<year></year>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[CRI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Falchi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Offner]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Belada]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with highrisk diffuse large B-cell lymphoma (DLBCL): phase 1/2 data update]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2022</year>
<volume>40</volume>
<numero>16</numero>
<issue>16</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Susanibar-Adaniya]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Barta]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2021 Update on diffuse large B-cell lymphoma: a review of current data and potential applications on risk stratification and management]]></article-title>
<source><![CDATA[Am J Hematol]]></source>
<year>2021</year>
<volume>96</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>617629</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Polovich]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McNiff]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[LeFebvre]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
<name>
<surname><![CDATA[Charmaine Cummungs]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Bonelli]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards]]></article-title>
<source><![CDATA[Journal of Clinical Oncology]]></source>
<year>2009</year>
<volume>27</volume>
<numero>32</numero>
<issue>32</issue>
<page-range>5469-75</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Marie Mulvey]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Fall River]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Time to Focus on Inpatient Safety: Revision of the American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards]]></article-title>
<source><![CDATA[Journal of Clinical Oncology]]></source>
<year>2012</year>
<volume>30</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1021-2</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>Ministerio de Sanidad, Consumo y Bienestar Social</collab>
<source><![CDATA[Protocolo clínico para el manejo de los efectos adversos graves en pacientes tratados con medicamentos que contienen células T- CAR (Chimeric Antigen Receptor) ANTI-CD 19 (CART-19)]]></source>
<year>2019</year>
<publisher-name><![CDATA[Consejo Interterritorial del Sistema Nacional de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arroyo-Lucas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vásquez-Cruz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Becerril]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nájara-Ortiz]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patrones funcionales: una experiencia en el camino de la construcción del conocimiento]]></article-title>
<source><![CDATA[Rev Mex Enf]]></source>
<year>2018</year>
<volume>6</volume>
<page-range>97-102</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suarez Montero]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Caballero González]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Martín Aguilar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mancebo Cortés]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de neurotoxicidad asociada a células inmunoefectoras: un enfoque terapéutico en el paciente crítico]]></article-title>
<source><![CDATA[Medicina Intensiva]]></source>
<year>2022</year>
<volume>46</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>201-12</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[TA]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cold Spring Harbor Perspectives in Biology]]></article-title>
<source><![CDATA[Cytokines in Cancer Immunotherapy]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<collab>Leuk lymphoma Soc</collab>
<source><![CDATA[Immunotherapy Facts]]></source>
<year>2015</year>
<numero>9</numero>
<issue>9</issue>
<page-range>1-8</page-range><publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[LLS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castañeda de la Lanza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Shea]]></surname>
<given-names><![CDATA[C. GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Narváez Tamayo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano Herrera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Castañeda Peña]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Castañeda de la Lanza]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Calidad de vida y control de síntomas en el paciente oncológico]]></article-title>
<source><![CDATA[Gac Mex Oncol]]></source>
<year>2015</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>150-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eu Sylvia]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
<name>
<surname><![CDATA[Eu Juan Carlos]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Eu Aracely]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermería oncológica: estándares de seguridad en el manejo del paciente oncológico]]></article-title>
<source><![CDATA[Rev Médica Clínica Las Condes]]></source>
<year>2013</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>694-704</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
